<DOC>
	<DOC>NCT00211159</DOC>
	<brief_summary>Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients</brief_summary>
	<brief_title>OmegAD (Omega-3 and Alzheimer's Disease)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Alzheimer's disease with MMSE 1530, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for &gt;3 months and remaining on that treatment for the study period Already treated with omega3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Dietary supplementation</keyword>
	<keyword>Cognition</keyword>
	<keyword>Safety</keyword>
</DOC>